Arcadia Biosciences, Inc.

RKDA Consumer Defensive Packaged Foods

Arcadia Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 3.71% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 35.9% and free cash flow grew 82.1%, each against the same quarter a year earlier.

0.17 0.03 −15.00%
Market cap
$490.0K
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
3/9
Altman Z
−59.20
Beneish M
−1.84
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 3 3 2

+8 more TTM periods

ROE
(430.93%) (158.15%) (45.14%) (64.99%)
ROA
(162.72%) (101.82%) (23.32%) (42.54%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(271.95%) (245.08%) (54.33%) (82.90%)
Average Days of Receivables
42.99 32.60 31.93 58.65
Free Cash Flow per Share
(0.85) (2.04) 0.56 (4.45)
Free Cash Flow
(2.54) (4.25) 0.76 (6.09)
Capital Expenditures
— — 5.50 —
Other line items
Cash ROIC
(52.71%) (64.35%) 8.74% (53.73%)
Accounts Receivable Turnover
5.21 4.66 6.07 6.04
Accounts Payable Turnover
2.11 2.08 1.59 1.74
Inventory Turnover
2.57 2.93 2.93 2.81
Average Days of Payables
162.63 129.09 210.78 228.62
Days of Inventory on Hand
109.36 98.40 142.80 165.31
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
114.75% 135.39% 144.11% 156.34%
Share Based Compensation of Revenue
2.09% 3.59% 4.82% 6.46%
Operating CF/Net income
0.23 0.46 2.03 1.20
Depreciation/Fixed assets
0.00 0.00 10.63 18.70
Capex/Depreciation
0.00 0.00 64.71 0.00
Revenue per Share
1.59 2.28 3.55 3.78
Operating CF per Share
(0.85) (2.04) (3.46) (4.45)
Capex per Share
0.00 0.00 4.02 0.00
Capex to Sales
0.00 0.00 (1.13) 0.00

Fold the line items

Columns are period end dates